Ignacio Melero - Nanotechnology

Author Information

Ignacio Melero is a researcher affiliated with the Department of Oncology at the University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), located in Pamplona, Spain. His work primarily focuses on cancer immunotherapy and related fields.

Research Contributions

Ignacio Melero has made significant contributions to the field of cancer immunotherapy. His research has explored various strategies to enhance the immune system's ability to fight cancer, including the use of interleukin-12, bispecific antibodies targeting PD-L1 and 4-1BB, and CD137 agonist immunotherapies. His studies often involve both preclinical characterization and clinical trials to validate novel therapeutic strategies. Notably, his work on the Tumor ENPP1(CD203a)/Haptoglobin Axis and its role in post-radiotherapy local recurrence in breast cancer showcases his dedication to understanding complex tumor-immune interactions. Additionally, his research extends to the characterization of immune responses in diseases like COVID-19, providing insights into immune circuits related to tissue injury.

Aliases

Ignacio Melero is also known by the names I Melero and I. Melero. These aliases are frequently used in his publications and professional references.

Publication and Citation Metrics

Metric	Value
Citation Count	32,149
H-Index	93
Paper Count	498

Publications:

Tumor ENPP1(CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer.

DOI: 10.1158/2159-8290.CD-21-0932

Year: 2022

Novel strategies exploiting interleukin-12 in cancer immunotherapy.

DOI: 10.1016/j.pharmthera.2022.108189

Year: 2022

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients With Advanced Refractory Solid Tumors.

DOI: 10.1158/2159-8290.CD-21-1345

Year: 2022

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

DOI: 10.1136/jitc-2021-003532

Year: 2022

Revisiting intracavitary immunotherapy of cancer.

DOI: 10.1158/1078-0432.CCR-22-0201

Year: 2022

Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

DOI: 10.7150/thno.63359

Year: 2022

Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers.

DOI: 10.1016/j.esmoop.2022.100419

Year: 2022

Tumor ENPP1(CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer.

DOI: 10.1158/2159-8290.CD-21-0932

Year: 2022

Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune circuits related to tissue injury

DOI: 10.1101/2021.06.21.449178

Year: 2021

Intratumoural administration and tumour tissue targeting of cancer immunotherapies

DOI: 10.1038/s41571-021-00507-y

Year: 2021

What Role Do Nanoarrays Play?

How Can Nanotechnology Aid in Tissue Engineering?

How Does Nanotechnology Aid in Gene Editing?

How is the Global Market Distributed?

What Are Some Key Research Centers at MIT?

What Techniques are Used to Control Crystallization?

How Does ICP-OES Work?

What is the Role of Nanomaterials in Flexible Displays?

How Can Nanotechnology Be Applied to Disease Prevention?

How Important is the Sample’s Physical State?

Partnered Content Networks

Relevant Topics